In Depth 1 Nov 2024 Can AI cure Alzheimer’s disease? …AI platform, Centaur Chemist, uses predictive modeling to streamline the selection of candidate compounds. This platform has already brought three AI-designed drug candidates to clinical testing, including DSP-0038 for Alzheimer’s… November 1, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 …alike. U.S.-based MBX’s $187.7 million offering will fund its lead candidate MBX 2109 – hoping to take on Yorvipath – into phase 3 studies. The IPO was following the news… November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 May 2023 5 cell therapy companies you should know about …pipeline includes candidates being investigated for the treatment of synovial sarcoma, head and neck cancer, esophageal cancer, ovarian cancer, and more. Afamitresgene autocel is the company’s first-generation TCR T-cell therapy… May 10, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023 Genoscience Pharma receives orphan drug designation for hepatocellular carcinoma drug Genoscience Pharma has announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA)… February 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2024 Eight areas where gene therapy shines …Administration (FDA) in 2023. Pfizer is also advancing giroctocogene fitelparvovec, a candidate for the same indication, and recently reported positive phase 3 data. Gene therapy for neurological disorders Neurological disorders… November 21, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Cyxone receives approval for phase 2b rheumatoid arthritis study …and multiple sclerosis. Rabeximod is a phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a phase 1 candidate drug for treatment of multiple sclerosis…. September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has… December 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies …portfolio and the option to gain rights for additional targets, up to a total of eight nanobody candidates. If Sanofi opts in for all eight candidates and they reach commercialization,… July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 17 Jul 2017 Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares …of GPCRs are activated by hormones,” said Marshall, “and endocrine diseases are an example of smaller indications where we can more easily take candidates through all the way to the… July 17, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 iNtRON looks to control colorectal cancer through microbiome iNtRON Biotechnology has announced that it has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate from iNtRON Biotechnology’s PHAGERIA platform technology, which is… April 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2025 Fusion proteins attract funds and biopharma partnerships …central nervous system-focused pipeline, which consists of fusion proteins. The preclinical-stage biotech’s lead candidate is ILM01, a fusion protein that targets protein fragments called amyloid beta that are the hallmark… August 6, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 OneThree Biotech completes build and optimization of AI model for RSV data …infection and then identify drugs that can effectively reverse those signatures with therapeutically meaningful benefits with a view to then adding such identified drugs to Poolbeg’s pipeline. Producing candidates quickly… June 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email